Actuate Therapeutics and The University of Kansas Cancer Center announced the enrollment of the first patient on a Phase...

Read more

Actuate Therapeutics, Inc. announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met...

Read more

Actuate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for...

Read more

Actuate Therapeutics, Inc. announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study...

Read more

Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...

Read more

We are delighted to announce that Actuate Therapeutics is the latest company to join the Kairos portfolio. Founded in...

Read more